Inmunodeficiencia primaria combinada: presentación de un caso

Marsán Suárez, Vianed; Villaescusa Blanco, Rinaldo; Valle Pérez, Lázaro O del; Arce Hernández, Ada A; Torres Leyva, Isabel; Macías Abraham, Consuelo.
Rev. cuba. hematol. inmunol. hemoter ; 17(1)ene.-abr. 2001.
Artículo en Español | CUMED | ID: cum-34238

Documentos relacionados

  1. [Treatment of Patients with Immunodeficiency].
  2. [Immunglobulin Substitution Therapy in Hematological Patients with secondary Antibody Deficiency].
  3. Antibody deficiency testing for primary immunodeficiency: A practical review for the clinician.
  4. A Multi­Center, Open­Label, Single­Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency.
  5. Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study.
  6. Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment.
  7. Efficacy of Bortezomib for Treating Anti-Interferon-Gamma Autoantibody-Associated Adult-Onset Immunodeficiency Syndrome.
  8. Rethinking PIDs: Why the distinction between primary and secondary immune disorders is more frequently relevant than that between inborn and acquired errors of immunity.
  9. [General concepts of humoral immune deficiencies].
  10. Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens.